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Introduction 
Among all the most common cardiovascular diseases is ischemic heart disease (ICP). 
At present, there is a process of "rejuvenation" of the ICC, occupying important 
positions in society, which is why the given disease needs to be considered as one 
with important social value. 
Purpose 
Conduct a randomized clinical trial of the efficacy and harmlessness of 
inclusion in standardized pharmacotherapy of mildronate in patients with 
stable angina pectoris.  
Material and methods 
An open randomized clinical trial was performed that included 160 patients with 
CPI (117 men and 43 women) with a mean age of 59.26 ± 0.74 years. 142 patients 
had stable angina pectoris from different functional classes, and 21 - unstable 
angina pectoris. The control group included 30 practically healthy people. The 
observation period was 6 weeks. 
Results 
There was a significant decrease in serum concentrations of organospecific 
myocardial enzymes - CFK-MB and LDH1, which speaks of the reduction of "leakage" 
of enzymes from the cytoplasm of cells following the stabilization of cardiomyocyte 
membranes. A significant decrease in the plasma concentration of pyruvate was 
detected, and in the mitochondria - the activation of PDH, indicating the stimulation 
of the oxidative decarboxylation process of pyruvate. Also, in mitochondria a 
significant activation of CS and insignificant SDH was revealed. 
Conclusions 
In patients with myocardial ischemia mildronate activates glycolysis, oxidative 
phosphorylation and oxidative decarboxylation, stabilizes the cardiomyocyte 
membrane, reduces the degree of hypoxia, restoring the level of ATP and adequate 
energy intake to the myocardium 
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